The All-in-One Screener can be used to find insider buys and sales over the last week by clicking on the Insiders tab and changing the settings for All Insider Buying to “$1,000,000+” and duration to "February 2016."
According to the above filters, the following are the recent buys from company insiders in the past week.
On Feb. 12 and 18, Energy Capital Partners a director and 10% owner of Summit Midstream Partners LPÂ (SMLP), bought 436,394 shares of the company at the price of $15.23 per share. Since then, the price of the stock has risen by 4.4% to $15.86 per share.
The company has an insider ownership of 0.13% and an institutional ownership of 56.08%.
It is a limited partnership focused on owning and operating midstream energy infrastructure that is strategically located in the core producing areas of unconventional resource basins, primarily shale formations, in North America.
During the last 12 months, the price of the stock has dropped by 59% and is now trading with a forward P/E ratio of 8.15. The price is 59.93% below its 52-week high and 23.71% above its 52-week low.
On Feb. 18, John Charman, CEO of Endurance Specialty Holdings Ltd. (ENH), bought 84, 203 shares of the company at the price of $61.48 per share. Since then, the price of the stock has risen by 0.7% to $61.76 per share.
The company has an insider ownership of 3.9% and an institutional ownership of 95.25%.
The company's business is organized into two business segments: Insurance and Reinsurance.
During the last 12 months, the price of the stock has dropped by 3% and is now trading with a P/E ratio of 9.77. The price is 12.40% below its 52-week high and 6.54% above its 52-week low.
RS Investment Management (Trades, Portfolio) is the largest shareholder of the company among the gurus with 1.43% of outstanding shares, followed by Donald Smith (Trades, Portfolio) with 1.36%, Diamond Hill Capital (Trades, Portfolio) with 1.28%, Richard Pzena (Trades, Portfolio) with 1.14%, David Dreman (Trades, Portfolio) with 0.27% and Jeremy Grantham (Trades, Portfolio) with 0.23%.
On Feb. 12 and 18, Robert Rowling, a 10% owner of Northern Oil & Gas Inc. (NOG), bought 818,016 shares of the company at the price of $2.90 per share. Since then, the price of the stock has risen by 7.6% to $3.04 per share.
The company has an insider ownership of 13.41% and an institutional ownership of 80.35%.
The company is engaged in the acquisition, exploration, development and production of crude oil and natural gas properties, primarily in the Bakken and Three Forks formations within the Williston Basin in North Dakota and Montana.
During the last 12 months, the price of the stock has dropped by 65% and is now trading with a forward P/E ratio of 500. The price is 68.03% below its 52-week high and 52.76% above its 52-week low.
Mairs and Power (Trades, Portfolio) is the largest shareholder among the gurus with 0.4% of outstanding shares, followed by Jeremy Grantham (Trades, Portfolio) with 0.08% and Paul Tudor Jones (Trades, Portfolio) with 0.03%.
On Feb. 17, Felix Baker, a director and 10% owner of Seattle Genetics Inc. (SGEN), bought 1,269,147 shares of the company at the price of $30.43 per share. Since then, the price of the stock has dropped by 1.9% to $29.84 per share.
The company has an insider ownership of 1.30% and an institutional ownership of 99.46%.
It is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer.
During the last 12 months, the price of the stock has dropped by 7% and is now trading with a P/B ratio of 6.39. The price is 39.59% below its 52-week high and 21.48% above its 52-week low.
The largest shareholder among the gurus is PRIMECAP Management (Trades, Portfolio) with 9.24% of outstanding shares, followed by Columbia Wanger (Trades, Portfolio) with 1.16% and Manning & Napier Advisors with 0.18%.
On Feb. 12, Berkshire Hathaway (BRK.A) (BRK.B), a 10% owner of Phillips 66Â (PSX), bought 1079,478 shares in the company at the price of $72.91 per share. Since then, the price of the stock has risen by 9% to $79.44 per share.
The company has an insider ownership of 0.06% and an institutional ownership of 77.06%.
During the last 12 months, the price of the stock has risen by 6% and is now trading with a P/E ratio of 9.21. The price is 14.38% below its 52-week high and 15.47% above its 52-week low.
Warren Buffett (Trades, Portfolio) is the largest shareholder of the company among the gurus with 14.16% of outstanding shares, followed by James Barrow (Trades, Portfolio) with 2.87%, First Pacific Advisors (Trades, Portfolio) with 0.56%, Jim Simons (Trades, Portfolio) with 0.22%, NWQ Managers (Trades, Portfolio) with 0.12%, Pioneer Investments (Trades, Portfolio) with 0.11%, Tweedy Browne (Trades, Portfolio) with 0.07%, Tweedy Browne (Trades, Portfolio) Global Value with 0.06%, John Hussman (Trades, Portfolio) with 0.02% and John Burbank (Trades, Portfolio) with 0.01%.
On Feb. 12, John Barry, CEO of Prospect Capital Corp. (PSEC), bought 1,058,000 shares in the company at the price of $6.15 per share. Since then, the price of the stock has risen by 10.7% to $6.81 per share.
The company has an insider ownership of 3.29% and an institutional ownership of 16.41%.
The company provides capital to middle-market companies and private equity financial sponsors for refinancing, leveraged buyouts, acquisitions, recapitalizations, later-stage growth investments, and capital expenditures.
During the last 12 months, the price of the stock has dropped by 25% and is now trading with a P/E ratio of 21.26. The price is 25.54% below its 52-week high and 26.49% above its 52-week low.
The largest shareholder among the gurus is David Dreman (Trades, Portfolio) with 0.06% of outstanding shares, followed by Manning & Napier Advisors with 0.03% and Joel Greenblatt (Trades, Portfolio) with 0.01%.
On Feb. 12, Julian Baker, director and 10% owner of Incyte Corp. (INCY), bought 2,251,427 shares in the company at the price of $63.53 per share. Since then, the price of the stock has risen by 11.8% to $71.02 per share.
The company has an insider ownership of 1.48% and an institutional ownership of 98.25%.
It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.
During the last 12 months, the price of the stock has dropped by 7% and is now trading with a forward P/E ratio of 46.30. The price is 44.28% below its 52-week high and 35.36% above its 52-week low.
Vanguard Health Care Fund (Trades, Portfolio) is the largest shareholder of the company among the gurus with 5.14% of outstanding shares, followed by Frank Sands (Trades, Portfolio) with 2.36% and Ken Fisher (Trades, Portfolio) with 0.01%.
